Dendritic Cells in Oncolytic Virus-Based Anti-Cancer Therapy
AbstractDendritic cells (DCs) are specialized antigen-presenting cells that have a notable role in the initiation and regulation of innate and adaptive immune responses. In the context of cancer, appropriately activated DCs can induce anti-tumor immunity by activating innate immune cells and tumor-specific lymphocytes that target cancer cells. However, the tumor microenvironment (TME) imposes different mechanisms that facilitate the impairment of DC functions, such as inefficient antigen presentation or polarization into immunosuppressive DCs. These tumor-associated DCs thus fail to initiate tumor-specific immunity, and indirectly support tumor progression. Hence, there is increasing interest in identifying interventions that can overturn DC impairment within the TME. Many reports thus far have studied oncolytic viruses (OVs), viruses that preferentially target and kill cancer cells, for their capacity to enhance DC-mediated anti-tumor effects. Herein, we describe the general characteristics of DCs, focusing on their role in innate and adaptive immunity in the context of the TME. We also examine how DC-OV interaction affects DC recruitment, OV delivery, and anti-tumor immunity activation. Understanding these roles of DCs in the TME and OV infection is critical in devising strategies to further harness the anti-tumor effects of both DCs and OVs, ultimately enhancing the efficacy of OV-based oncotherapy. View Full-Text
Share & Cite This Article
Kim, Y.; Clements, D.R.; Sterea, A.M.; Jang, H.W.; Gujar, S.A.; Lee, P.W.K. Dendritic Cells in Oncolytic Virus-Based Anti-Cancer Therapy. Viruses 2015, 7, 6506-6525.
Kim Y, Clements DR, Sterea AM, Jang HW, Gujar SA, Lee PWK. Dendritic Cells in Oncolytic Virus-Based Anti-Cancer Therapy. Viruses. 2015; 7(12):6506-6525.Chicago/Turabian Style
Kim, Youra; Clements, Derek R.; Sterea, Andra M.; Jang, Hyun W.; Gujar, Shashi A.; Lee, Patrick W.K. 2015. "Dendritic Cells in Oncolytic Virus-Based Anti-Cancer Therapy." Viruses 7, no. 12: 6506-6525.